trending Market Intelligence /marketintelligence/en/news-insights/trending/RaVUV7jARaYWZ-m34SKYpg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Becton Dickinson, Bard deal gets conditional nod from EU regulator

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Becton Dickinson, Bard deal gets conditional nod from EU regulator

The European Commission granted conditional approval to Becton Dickinson and Co.'s $24 billion acquisition of C. R. Bard Inc.

As part of the clearance, Becton Dickinson must divest its core needle biopsy devices business and tissue marker product line.

Closing of the deal is expected to occur in the fourth calendar quarter of 2017, subject to customary closing conditions and additional regulatory approvals, including the U.S. Federal Trade Commission and other regulatory bodies.